x

Coronavirus

Israel Has Approved Moderna COVID-19 Vaccine

JERUSALEM — American biotech company Moderna says Israel has approved its COVID-19 vaccine, but the announcement comes as the country faces a rapidly growing outbreak of the disease.

Moderna said in a statement Tuesday that the Israeli Health Ministry authorized use of the company’s vaccine and that it would begin delivering this month the 6 million doses secured by Israel.

Israel’s Health Ministry reported 8,308 new confirmed cases of coronavirus on Tuesday — one of the highest daily tallies since the beginning of the pandemic — as the country struggles to contain the pandemic during a third national lockdown. Israel has recorded over 450,000 cases of coronavirus and 3,445 deaths.

At the same time, Israel has already vaccinated over 10% of its population, primarily the elderly and healthcare workers.

RELATED

WASHINGTON (AP) — Anthony Fauci, former chief White House medical adviser, is expected to testify before Congress early next year as part of Republicans' yearslong investigation into the origins of COVID-19 and the U.

Top Stories

Columnists

A pregnant woman was driving in the HOV lane near Dallas.

General News

FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.

Video

Echoes of Asia Minor: Life, Catastrophe and Resilience Opens at Consulate in NYC

NEW YORK – Consul General of Greece in New York Dinos Konstantinou in collaboration with the Greek Orthodox Archdiocese of America hosted the opening reception of the moving exhibition Echoes of Asia Minor: Life, Catastrophe and Resilience on November 29 at the Consulate General of Greece in New York.

NEW YORK – The Hellenic Film Society USA presents Maria by Callas, the acclaimed documentary that tells the life story of the legendary Greek-American opera singer.

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. [email protected]

You may unsubscribe at any time using the link in our newsletter.